<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THIOGUANINE (TG, 6-THIOGUANINE)</span><br/>(thye-oh-gwah'neen)<br/><span class="topboxtradename">Lanvis <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Tabloid<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite; purine antagonist</span><br/><b>Prototype: </b>Mercaptopurine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antimetabolite and purine antagonist with immunosuppressive activity. Highly toxic. Drug is incorporated into the DNA and
         RNA of human bone marrow cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Delays myelosuppression; has potential mutagenic and carcinogenic properties. Normally accompanied by evidence of toxicity.</p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other antineoplastics for remission induction in acute myelogenous leukemia and as treatment of chronic
         myelogenous leukemia. Has little advantage over mercaptopurine.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with prior resistance to this drug. Pregnancy (category D), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Leukemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 mg/kg/d, may increase to 3 mg/kg/d if no response after 4 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Withhold drug and notify physician if toxicity develops. There is no known antagonist; prompt discontinuation of the drug
            is essential to avoid irreversible myelosuppression from toxicity.
         </li>
<li>Store at 15°30° C (59°86° F) in airtight container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-life">Leukopenia, thrombocytopenia,</span> anemia. <span class="typehead">GI:</span> Jaundice, nausea, vomiting, anorexia, stomatitis, diarrhea. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Hyperuricemia</span>. <span class="typehead">Other:</span> Hepatotoxicity (risk increased with long-term use). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Severe hepatotoxicity with <b>busulfan;</b> may decrease immune response to <span class="classification">vaccines</span>; increase risk of bleeding with <span class="classification">anticoagulants</span>; <span class="classification">nsaid</span>s, <span class="classification">salicylates</span>; <span class="classification">platelet inhibitors</span>, <span class="classification">thrombolytic agents</span>; effects may be reversed by <b>filgrastim,</b>
<b>sargramostim.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Variable and incomplete absorption from GI tract. <span class="typehead">Peak:</span> 8 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 11 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor blood counts weekly (CBC with differential and platelet count); periodic LFTs with long-term use.</li>
<li>Determine hematologic parameters for withholding drug.</li>
<li>Monitor I&amp;O ratio and report oliguria.</li>
<li>Observe patient's skin and sclera for jaundice. It should be reported promptly as a symptom of toxicity; drug will be discontinued
            promptly.
         </li>
<li>Expect that the drop in leukocyte count may be slow over a period of 24 wk. Treatment is interrupted if there is a rapid
            fall within a few days.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Maintenance doses are continued throughout remissions.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>